Skip to content

EU Commission Secures Vaccine Production Capacity For Future Crises

Pfizer and European pharmaceutical firms to stockpile vaccines for rapid response, raising concerns over equity

The European Commission has reportedly made arrangements with Pfizer Inc (NYSE: PFE) and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually for potential future global health crises.

Under the agreement, companies will maintain their facilities in a state of readiness, monitor supply chains, and stockpile as needed, to enable rapid production if a new public health crisis arises, Reuters reported.

However, vaccine equity activists caution that this plan could repeat the “vaccine apartheid” observed during the COVID-19 crisis.

Pfizer’s plants in Ireland and Belgium have been chosen by the Commission to reserve mRNA vaccine production capacity; Spanish firms Reig Jofre and Laboratorios Hipra SA have been chosen for protein-based vaccine capacity and Bilthoven Biologicals B.V. of the Netherlands for vector-based vaccines.

Pfizer acknowledges the urgent need for improved pandemic preparedness and response planning and asserts that it has taken significant measures to prepare for potential future global disease outbreaks without specifying these measures.

Reig Jofre reveals that its deal with the EU reserves capacity for four years, with the option to extend up to a maximum of eight years, though financial details were undisclosed.

SUQIAN, CHINA – JUNE 11, 2023 – Illustration: BioNTech, Suqian, Jiangsu Province, China, June 11, 2023. In May, the European Commission agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. PHOTO BY CFOTO/GETTY IMAGES  

The World Health Organization has recommended that governments and manufacturers reserve up to 20% of any tests, vaccines, or treatments for distribution in poorer nations to avoid a recurrence of the “catastrophic failure” experienced during the COVID-19 pandemic. This suggestion is part of a draft global pandemic agreement currently under discussion.


Produced in association with Benzinga

“What’s the latest with Florida Man?”

Get news, handpicked just for you, in your box.

Check out our free email newsletters

Recommended from our partners